metastatic melanoma
Human disease
Ratings
0
Nobody has rated this yet. Be the first!
Subject of
10
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
BRAF inhibitor activity in V600R metastatic melanoma
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Fibroblast Growth Factor Receptor 3 Amplified Metastatic Melanoma Treated With Erdafitinib
Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review
Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma
Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing
